drugset / Trial / NCT05817955
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
Phase 2
Recruiting
50 enrolled
The First Affiliated Hospital with Nanjing Medical University
Affiliated Hospital of Jiangsu University · collabJiangning Hospital Affiliated to Nanjing Medical University · collabThe Second Hospital of Nanjing Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study observes the safety and efficacy of Azacitidine (AZA) combined with ruxolitinib to treat higher-risk Myelodysplastic Syndromes∕Myeloproliferative Neoplasms(MDS/MPN)
Timeline
- Start
- 2022-11-01
- Primary completion
- 2025-01-01
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 20 mg | Oral |